A six-month, placebo-controlled trial of d-cycloserine co-administered with conventional antipsychotics in schizophrenia patients-Reference-Cited by-同舟云学术

A six-month, placebo-controlled trial of d-cycloserine co-administered with conventional antipsychotics in schizophrenia patients

Published:2004-10-21 Issue:1 Volume:179 Page:144-150
ISSN:0033-3158
Container-title:Psychopharmacology
language:en
Short-container-title:Psychopharmacology

Author:

Goff Donald C.,Herz Lawrence,Posever Thomas,Shih Vivian,Tsai Guochuan,Henderson David C.,Freudenreich Oliver,Evins A. Eden,Yovel Iftah,Zhang Hui,Schoenfeld David

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s00213-004-2032-2.pdf

Reference37 articles.

1. Andreasen N (1984) Modified scale for the assessment of negative symptoms. National Institutes of Mental Health publication ADEM 9?102

2. van Berckel BN, Hijman R, van der Linden JA, Westenberg HG, van Ree JM, Kahn RS (1996) Efficacy and tolerance of d-cycloserine in drug-free schizophrenic patients. Biol Psychiatry 40:1298?1300

3. van Berckel BNM, Evenblij CN, van Loon BJAM, Maas MF, van der Geld MAM, Wynne HJ, van Ree JM, Kahn RS (1999) d-Cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study. Neuropsychopharmacology 21:203?210

4. Cascella NG, Macciardi F, Cavallini C, Smeraldi E (1994) d-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study. J Neural Transm [Gen Sect] 95:105?111

5. Chessell I, Procter A, Francis P, Bowen D (1991) d-Cycloserine, a putative cognitive enhancer, facilitates activation of the N-methyl-d-aspartate receptor-ionophore complex in Alzheimer brain. Brain Res 565:345?348

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dysfunction of the NMDA Receptor in the Pathophysiology of Schizophrenia and/or the Pathomechanisms of Treatment-Resistant Schizophrenia;Biomolecules;2024-09-06

2. Passing the torch: The ascendance of the glutamatergic synapse in the pathophysiology of schizophrenia;Biochemical Pharmacology;2024-06

3. The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial;Neuropsychopharmacology;2023-03-16

4. Rational and Translational Implications of D-Amino Acids for Treatment-Resistant Schizophrenia: From Neurobiology to the Clinics;Biomolecules;2022-06-29

5. Perspective Chapter - NMDA Treatments for CNS Disorders;Ketamine Revisited - New Insights into NMDA Inhibitors [Working Title];2021-10-28